Arabic Arabic English English French French German German
dark

Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor

The clinical trials of KRAS G12C inhibitors are expected to enroll patients in the second half of 2021. Jacobio is aiming for the in-house combination therapy of KRAS G12C and SHP2 inhibitors. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

Next Post

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

Related Posts
Total
0
Share